Sek Kathiresan, chief executive of Verve Therapeutics and head of obesity research and early development at Eli Lilly, explains how protective genetic variants led to a one-time in vivo gene-editing therapy for heart disease despite early doubts. He discusses the biological, technological, regulatory and commercial risks, the phase 1 results for Verve-102 and the case for lifelong LDL lowering given cumulative exposure, what recent failures of genetically validated targets and the Lp(a) trial leave unanswered, who benefits most according to polygenic risk scores, and whether one-time gene therapy could work for obesity.
Published Oct 29, 2026 · 36 min